NDAQ Stock Recent News

CALGARY, Alberta, April 17, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease and gout, announces receipt of notification from the Nasdaq Stock Market LLC Listing Qualifications Department that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Rule 5550(a)(2) since the closing bid price for the Company's common shares listed on Nasdaq was below US$1.00 for 30 consecutive business days. Nasdaq Rule 5550(a)(2) requires the shares to maintain a minimum bid price of US$1.00 per share, and Nasdaq Rule 5810(c)(3)(A) provides that failure to meet such a requirement exists when the bid price of the shares is below US$1.00 for a period of 30 consecutive business days.

THE WOODLANDS, TX, April 17, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that the Compensation Committee of Autonomix's Board of Directors approved the grant of an inducement stock option on April 17, 2025 to purchase 5,000 shares of the Company's common stock, to a new non-executive employee pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception, as a component of the individual's employment compensation and was granted as an inducement material to their start of employment with the Company.

MIAMI, April 17, 2025 (GLOBE NEWSWIRE) -- Motorsport Games Inc. (“Motorsport Games” or “the Company”), the racing game developer and publisher of prominent simulation racing (or “sim racing”) titles including Le Mans Ultimate, is pleased to announce that it has regained compliance with the stockholders' equity requirement of the Nasdaq Stock Market (“Nasdaq”) as set forth in Nasdaq Listing Rule 5550(b)(1).

Vincerx common stock suspended by Nasdaq inadvertently; will resume trading at the open of business on April 21, 2025

WALTHAM, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced that on April 15, 2025 (the “Grant Date”), the Compensation Committee of the Company's Board of Directors (the “Committee”) granted non-qualified stock options to two newly hired officers of the Company, each as an inducement material to each officer's entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4).

NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Nvni Group Limited (Nasdaq: NVNI) (“Nuvini” or the “Company”), a leading acquirer of private SaaS B2B companies in Latin America, has received notice from the listing qualifications department staff of The Nasdaq Stock Market ("Nasdaq") stating that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1 per share, and Listing Rule 5550(b)(2), which requires listed securities to maintain a minimum Market Value of Listed Securities (MVLS) of $35 million.

The Notification Letter has no immediate effect on the Company's listing on the Nasdaq Capital Market at this time, nor are the Company's business operations affected by receipt of the Notification Letter TEL AVIV, Israel and RALEIGH, N.C. , April 17, 2025 /PRNewswire/ --  RedHill Biopharma Ltd.

Company Celebrates Transition to a Public Company; Shares Trade Under “CHA” Ticker Company Celebrates Transition to a Public Company; Shares Trade Under “CHA” Ticker

Nasdaq pressured by tech losses, S&P 500 vulnerable. Google faces DOJ breakup risk, while traders brace for Netflix earnings after market close today.

Nasdaq (NDAQ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.